News

Business Wire

Tevogen Bio’s TVGN-489, an Allogeneic SARS-CoV-2 Specific Cytotoxic T Cell Therapy, Demonstrates Strong Anti-Viral Activity in Preclinical Study, as Presented by Professor ...

METUCHEN, N.J.--(BUSINESS WIRE)--Tevogen Bio, a clinical stage biotechnology company, announced that its investigational COVID-19 therapy, TVGN-489, demonstrated strong antiviral activity against SARS ...
Business Wire

Tevogen Bio to Initiate Clinical Trial of its Investigational T Cell Therapy for COVID-19 at Thomas Jefferson University

METUCHEN, N.J.--(BUSINESS WIRE)--Tevogen Bio, a clinical stage biotechnology company, announced the forthcoming clinical trial of TVGN-489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic ...